Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: J Thorac Oncol. 2017 Jan 11;12(5):872–877. doi: 10.1016/j.jtho.2017.01.004

Figure 1.

Figure 1

ROS1 rearrangements are generally mutually exclusive with oncogenic driver alterations in EGFR, KRAS, and ALK. One case (patient 53) in the MGH cohort had ROS1 testing that was positive by FISH (dark grey) but negative by NGS (purple). This case was found to harbor a KRAS G13D mutation (red) and an EGFR C781F mutation of unknown significance (blue). Another case (patient 48) had a KRAS I24N mutation of unknown significance (blue). All other ROS1-rearranged NSCLC cases in the MGH cohort tested negative (white) for concurrent EGFR and KRAS mutations and ALK rearrangements.